Just hit the 52 week low of $1.65. Sold off their Life Sciences division at a loss. In huge debt. Got rid of the CFO. Constant layoffs. According to Glassdoor, shuttling those jobs overseas to Serbia, Israel and India, and not really thinking about brain drain for top products like Proquest, Web of Science, Ex Libris, Derwent, others. Consulting divisions never making money/poor management. Highly leveraged and low organic growth. Can it get worse? Now to my question: is it a buy? Ratings are p
CryptoAlerta — análise de criptomoedas e mercado em tempo real